Fosphenytoin Sodium interactions
Checked as Fosphenytoin in this data source.
Full monograph for Fosphenytoin SodiumCheck it against another medicine
Medicines
570 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abemaciclib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abemaciclib and its pharmacologically active… | 6 sources — open the full entry |
| Abiraterone Acetate | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abiraterone, which is partially metabolized by the… | 8 sources — open the full entry |
| Acalabrutinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 7 sources — open the full entry |
| Alpelisib | Major | Metabolism | Coadministration of alpelisib with potent inducers of CYP450 3A4 may significantly reduce the plasma concentrations of alpelisib. The proposed mechanism, based… | 8 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Metabolism | Coadministration of amiodarone and phenytoin may alter the plasma concentrations of both drugs. Specifically, phenytoin concentrations may increase due to… | 34 sources — open the full entry |
| Amlodipine Besilate | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms | 47 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Major | Metabolism · Unknown | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms | 35 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Apixaban | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of apixaban… | 8 sources — open the full entry |
| Apremilast | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of apremilast, which is primarily metabolized by the… | 5 sources — open the full entry |
| Artemether + Lumefantrine | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are…2 documented mechanisms | 10 sources — open the full entry |
| Asciminib | Major | Metabolism | Coadministration of asciminib with CYP450 2C9 substrates that are also potent CYP450 3A4 inducers such as phenytoin or fosphenytoin may lead to altered plasma… | 1 sources — open the full entry |
| Avatrombopag | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Axitinib | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily… | 9 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Bortezomib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily… | 10 sources — open the full entry |
| Brigatinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brigatinib, which is partially metabolized by the… | 9 sources — open the full entry |
| Cabozantinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 7 sources — open the full entry |
| Capmatinib Hydrochloride | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Caspofungin Acetate | Major | Metabolism | Coadministration with inducers or mixed inducer/inhibitors of certain metabolic pathways may produce clinically meaningful reductions in the plasma… | 1 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration of cenobamate and phenytoin may lead to increased plasma concentrations of phenytoin and reduced plasma concentrations of cenobamate. The… | 17 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. | 3 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by… | 6 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may… | 65 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly reduce the bioavailability of dabigatran following oral administration of… | 5 sources — open the full entry |
| Daclatasvir | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Darolutamide | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of… | 6 sources — open the full entry |
| Dasatinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of dasatinib, which is primarily metabolized by the… | 11 sources — open the full entry |
| Deflazacort | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active… | 6 sources — open the full entry |
| Desogestrel | Major | Antagonism | Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the… | 33 sources — open the full entry |
| Dienogest | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…2 documented mechanisms | 98 sources — open the full entry |
| Dienogest + Estradiol Valerate | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 148 sources — open the full entry |
| Drospirenone | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may… | 65 sources — open the full entry |
| Drospirenone + Estetrol | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may… | 65 sources — open the full entry |
| Drospirenone + Estradiol | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…2 documented mechanisms | 115 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…2 documented mechanisms | 65 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…3 documented mechanisms | 91 sources — open the full entry |
| Elacestrant | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elacestrant, which is primarily… | 1 sources — open the full entry |
| Erdafitinib | Major | Metabolism | Coadministration with potent inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is… | 2 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Major | Antagonism · Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…2 documented mechanisms | 98 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may… | 65 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may…2 documented mechanisms | 65 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mg | Major | Metabolism | RECOMMENDED: Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may… | 65 sources — open the full entry |
| Everolimus | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects… | 6 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with enzyme-inducing anticonvulsants may decrease the plasma concentrations of opioids that are primarily metabolized by CYP450 3A4 such as… | 26 sources — open the full entry |
Food & lifestyle
alcohol
ModerateMetabolism
Acute consumption of alcohol may increase plasma phenytoin levels. Chronic consumption of alcohol may decrease plasma phenytoin levels. The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration. Other hydantoin derivatives may be similarly affected by ethanol.
What to do: Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.
5 sources
- Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7
- Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52
- "Product Information. Dilantin (phenytoin)." Parke-Davis (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0